A carregar...
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects...
Na minha lista:
| Publicado no: | J Ovarian Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6882236/ https://ncbi.nlm.nih.gov/pubmed/31775908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0594-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|